Search En menu ClientConnect
Close ClientConnect
Search
Search
Results
Top 5 search results See all results Advanced search
Top searches
    Most visited pages

        DRUG DISCOVERY RDI

        Signature(s)

        Amount
        € 75,000,000
        Countries
        Sector(s)
        France : € 15,000,000
        Germany : € 60,000,000
        Services : € 75,000,000
        Signature date(s)
        8/09/2017 : € 7,500,000
        8/09/2017 : € 7,500,000
        8/09/2017 : € 30,000,000
        8/09/2017 : € 30,000,000
        Link to source
        Data sheet
        DRUG DISCOVERY RDI
        Other links
        Related public register
        Environmental and Social Completion Sheet (ESCS) - DRUG DISCOVERY RDI
        Related press
        Germany: Investment Plan for Europe – EIB supports Evotec’s innovate strategy with EUR 75m loan

        Documents

        Environmental and Social Completion Sheet (ESCS) - DRUG DISCOVERY RDI
        Publication Date
        25 Dec 2021
        Document language
        English
        Main Topic
        Lending
        Document Number
        151791435
        Document Focus
        Environmental Information
        Document Type
        Environmental and Social Completion Sheet (ESCS)
        Publicly available
        Download now
        or Link to source
        Link to source
        Related public register
        Environmental and Social Completion Sheet (ESCS) - DRUG DISCOVERY RDI
        Other links
        Data sheet
        DRUG DISCOVERY RDI
        Related press
        Germany: Investment Plan for Europe – EIB supports Evotec’s innovate strategy with EUR 75m loan

        News & Stories

        Link to source
        Related press
        Germany: Investment Plan for Europe – EIB supports Evotec’s innovate strategy with EUR 75m loan
        Other links
        Data sheet
        DRUG DISCOVERY RDI
        Related public register
        Environmental and Social Completion Sheet (ESCS) - DRUG DISCOVERY RDI

        Photogallery

        More than 3,000 serious diseases currently have no cure. Evotec supports pharma and biotech companies, venture capital groups, academic institutions as well as foundations and not-for-profit organisations who develop drugs and therapeutics in areas of neuroscience, pain, oncology and infectious diseases. An EFSI-backed loan helps them to do so.
        Evotec
        ©Evotec

        General enquiries and comments

        The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
        Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
        Alternatively, the EIB can be contacted through its external offices.
        Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.

        Media enquiries

        Media-related enquiries can be addressed to the EIB Press Office. Please also visit our Media information section.

        Complaints mechanism

        Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.

        Zero tolerance against fraud and corruption

        The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Fraud and Investigation division. All complaints will be treated as strictly confidential and handled in line with the EIB investigation procedures and the Anti-Fraud Policy.

        Related publications